The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far. In Cohort 6, a durable clinical symptom response was observed 52 weeks...Read more
Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions were observed in 76% of patients and ctDNA clearance was observed in 59% of...Read more
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE...Read more
CAMBRIDGE, Mass. / Nov 14, 2025 / Business Wire / Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for...Read more
Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump Aims to Improve Patient and Clinician Experience for the Care of Diabetes SAN DIEGO, CA / ACCESS Newswire / November 14, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular...Read more
ROSA® Knee with OptimiZe™ Offers Personalized Surgical Planning and Drives Confidence in Delivering Accurate and Reproducible Outcomes1 WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Cidara Therapeutics | 111.81 105.49 | $217.80 |
| argenx | 16.25 1.82 | $907.98 |
| Madrigal Pharmaceuticals | 14.28 2.77 | $529.21 |
| Abivax | 9.49 9.41 | $110.39 |
| Praxis Precision Medicines | 8.34 4.68 | $186.42 |
| Celcuity | 8.15 9.48 | $94.15 |
| Movano Health | 7.59 244.05 | $10.70 |
| Scholar Rock | 7.34 24.41 | $37.41 |
| Krystal Biotech | 4.95 2.46 | $206.16 |
| Dianthus Therapeutics | 4.54 12.79 | $40.04 |
| Inhibrx | 4.51 6.04 | $79.13 |
| Avadel Pharmaceuticals | 4.32 22.45 | $23.56 |
| Belite Bio | 4.31 3.83 | $116.72 |
| United Therapeutics | 4.10 0.89 | $466.40 |
| Septerna | 4.03 20.95 | $23.27 |
| Bolt Biotherapeutics | 4.01 717.53 | $4.57 |
| Natera | 3.61 1.80 | $204.28 |
| Apollomics | 3.58 17.08 | $24.54 |
| Company | Volume | Last Trade |
|---|---|---|
| Invivyd | 436,158,439 | $2.35 |
| Applied Therapeutics | 266,713,563 | $0.23 |
| Pfizer | 95,524,872 | $25.10 |
| Clearmind Medicine | 83,923,864 | $0.28 |
| Anavex Life Sciences | 78,637,139 | $3.65 |
| Quantum-Si | 32,863,969 | $1.37 |
| Akebia Therapeutics | 31,022,358 | $1.67 |
| Recursion | 29,410,350 | $4.14 |
| Absci | 28,446,279 | $2.82 |
| Incannex Healthcare | 27,974,266 | $0.35 |
| Humacyte | 26,760,787 | $1.23 |
| Avadel Pharmaceuticals | 25,105,565 | $23.56 |
| Cidara Therapeutics | 24,906,375 | $217.80 |
| enVVeno Medical | 23,955,447 | $0.42 |
| Milestone Scientific | 21,295,728 | $0.34 |
| The Oncology Institute | 20,483,074 | $4.00 |
| Precigen | 19,233,176 | $4.84 |
| Bristol-Myers Squibb | 19,176,415 | $46.65 |
| Outlook Therapeutics | 18,855,749 | $1.59 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
